PO-02-083 LOCATION OF LEADLESS PACEMAKER IMPLANT AND PACING-INDUCED CARDIOMYOPATHY

Leadless pacing (LP) is associated with a lower incidence of pacing-induced cardiomyopathy (PICM) compared to transvenous pacing. However, it unclear if the location implantation LP makes difference in PICM. To compare PICM based on 276 patients [Men: 157 (57%), Women: 119 (43%), mean age: 73 ± 11 yrs, all EF > 50%] who received (Micra) between January 2019 – June 2022 formed study cohort. AV micra and VR were implanted 93 (34%) 183 (67%) respectively. Fluoroscopically, Interventricular septum was divided into 3 equal thirds [apical (AS), mid (MS) high (HS)]. During follow-up, defined as an left ventricular ejection fraction (EF) drop ≥ 10%. 94/276 (34%), 123/276 (45%), 59/276 (21%) had at AS, MS HS locations 8 5 months 23 (8.3%) developed (Men: 9/23 (39%), women: 14/23 (61%) (P = 0.023). Of them, 11/94 (12%), 8/123 (7%) 4/59 0.057) implantation. AS (11/94 (12%) higher risk MS+HS [12/182 0.044)]. The hazard [Adjusted Hazard ratio: 1.76 (1.13 - 3.25) P 0.044, (adjusted for age, gender, percentage burden EF)]. Incidence low (8.3%). Women are men. placement placement. Larger randomized studies needed confirm our findings.